13 August 2025
RNS
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
First Mexican Hospital Steriwave Deployment
Ondine Biomedical Launches ABC Medical Center Pilot of Steriwave® Nasal Photodisinfection
Ondine Biomedical Inc. (AIM: OBI) announces the American British Cowdray ("ABC") Medical Center in Mexico City will begin piloting Steriwave® nasal photodisinfection system in September. This marks the first hospital deployment of Steriwave in Mexico and will target the reduction of surgical site infections (SSIs) and healthcare-associated infections (HAIs) in orthopedic and neurosurgery patients.
With a population of approximately 132 million, Mexico's healthcare system is anchored by its private sector, which comprises approximately 3,000 private hospitals which perform around 25% of all surgeries annually. This private sector is crucial for high-income citizens and the thriving medical tourism industry, which attracts over 1.3 million international patients annually. A key challenge facing this sector is the high rate of surgical site infections (SSIs), which are nearly double those in the U.S. This issue is compounded by rising antimicrobial resistance (AMR), making advanced infection control a critical priority for hospitals, surgery centers, and clinics that serve this valuable market.
Carolyn Cross, CEO of Ondine, said:
"The Mexican market is a key pillar of our long-term strategic growth plans, and we are thrilled to partner with a world-class institution in ABC Medical Center. Their dedication to clinical excellence and patient safety makes them the ideal pilot partner for Steriwave's initiation in Mexico. This collaboration is a vital step in introducing our validated, non-antibiotic solution to a large market where combatting rising multidrug resistance is a top priority."
Dra. Roxana Trejo Gonzalez, Director of Infection Control at the ABC Medical Center , President of the Mexican Association for the Study of Nosocomial Infections (AMEXPE) and Co-founder of the Latin American Association for Infection Control (ASLACI) commented:
"Piloting Steriwave as a first in Mexico reflects our commitment to adopting evidence-based interventions against antimicrobial resistance. Reducing nasal pathogen load is a crucial step in preventing SSIs and protecting our local and international patients."
Steriwave has been deployed in leading hospitals in Canada, the UK, and other jurisdictions, with studies showing significant reductions in HAIs and no evidence of microbial resistance development. Steriwave is a non-antibiotic, light-activated therapy that decolonizes the nasal passages, a primary reservoir for multidrug-resistant organisms. The procedure involves applying a proprietary photosensitizer into the nares, followed by illumination with red light. This photochemical reaction generates singlet oxygen, rapidly inactivating bacteria, viruses, and fungi, without contributing to AMR.
About ABC Medical Center
Established in 1886, ABC Medical Center is a premier private healthcare provider in Mexico, operating two campuses with 850 beds. The institution is recognized for its advanced surgical programs, rigorous infection prevention protocols, and commitment to adopting innovative medical technologies to enhance patient outcomes.
Enquiries:
| Ondine Biomedical Inc. |
|
| Carolyn Cross, CEO |
+1 604 669 0555 |
| Strand Hanson Limited (Nominated & Financial Adviser) |
|
| James Harris, Richard Johnson |
+44 (0)20 7409 3494 |
| |
|
| Peel Hunt LLP (Broker & Joint Financial Adviser) |
|
| James Steel, Dr. Chris Golden |
+44 (0)20 7418 8900 |
| |
|
| Vane Percy & Roberts (Media Contact) |
|
| Simon Vane Percy |
+44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.